Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-124637
Filing Date
2024-11-12
Accepted
2024-11-12 08:13:21
Documents
81
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mreo-20240930.htm   iXBRL 10-Q 2077244
2 EX-31.1 mreo-ex31_1.htm EX-31.1 22451
3 EX-31.2 mreo-ex31_2.htm EX-31.2 21980
4 EX-32.1 mreo-ex32_1.htm EX-32.1 7610
5 EX-32.2 mreo-ex32_2.htm EX-32.2 7360
  Complete submission text file 0000950170-24-124637.txt   9428490

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT mreo-20240930.xsd EX-101.SCH 1528076
84 EXTRACTED XBRL INSTANCE DOCUMENT mreo-20240930_htm.xml XML 1683063
Mailing Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF
Business Address ONE CAVENDISH PLACE FOURTH FLOOR LONDON X0 W1G0QF 4403330237300
Mereo BioPharma Group plc (Filer) CIK: 0001719714 (see all company filings)

EIN.: 000000000 | State of Incorp.: X0 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38452 | Film No.: 241443620
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)